LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A10224615" target="_blank" >RIV/61989592:15110/11:10224615 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice?

Original language description

LDL-C is considered to be the major lipid risk factor and the main target of lipid-lowering therapy. Nevertheless, as all potentially atherogenic lipoprotein particles contain only one molecule of apoB and various amounts of cholesterol, apoB is a bettermarker of atherogenic particle numbers. Many laboratory, prospective and interventional studies have proved that apoB is a better indicator of cardiovascular risk than LDL-C. Statins lower LDL-C and non-HDL-C more (and to lower population percentile levels) than apoB. As a result, many patients treated with statins to achieve LDL-C and non-HDL-C targets remain at high risk owing to high levels of apoB, especially subjects with the prevalence of small dense LDL. With the worldwide increasing prevalenceof obesity and metabolic syndrome, the issue of appropriate risk markers and treatment goals is even more important.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FB - Endocrinology, diabetology, metabolism, nutrition

OECD FORD branch

—

Project

<a href="/en/project/NS10284" target="_blank" >NS10284: Dyslipidemia and prehypertension - association of dyslipidemic phenotypes with prevalence of prehypertension. Association of prehypertension with markers of insulin resistance, inflammation, endothelial dysfunction and subclinical atherosclerosis.</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2011

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Clinical Lipidology

ISSN

1758-4299

e-ISSN

—

Volume of the periodical

6

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

14

Pages from-to

35-48

UT code for WoS article

—

EID of the result in the Scopus database

—